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Abstract
There is extensive evidence implicating the intestinal microbiota in inflammatory bowel disease [IBD], but no microbial
agent has been identified as a sole causative agent. Bacteroidales are numerically dominant intestinal organisms that
associate with the mucosal surface and have properties that both positively and negatively affect the host. To determine
precise numbers and species of Bacteroidales adherent to the mucosal surface in IBD patients, we performed a
comprehensive culture based analysis of intestinal biopsies from pediatric Crohn’s disease [CD], ulcerative colitis [UC], and
control subjects. We obtained biopsies from 94 patients and used multiplex PCR or 16S rDNA sequencing of Bacteroidales
isolates for species identification. Eighteen different Bacteroidales species were identified in the study group, with up to ten
different species per biopsy, a number higher than demonstrated using 16S rRNA gene sequencing methods. Species
diversity was decreased in IBD compared to controls and with increasingly inflamed tissue. There were significant
differences in predominant Bacteroidales species between biopsies from the three groups and from inflamed and
uninflamed sites. Parabacteroides distasonis significantly decreased in inflamed tissue. All 373 Bacteroidales isolates collected
in this study grew with mucin as the only utilizable carbon source suggesting this is a non-pathogenic feature of this
bacterial order. Bacteroides fragilis isolates with the enterotoxin gene [bft], previously associated with flares of colitis, were
not found more often at inflamed colonic sites or within IBD subjects. B. fragilis isolates with the ability to synthesize the
immunomodulatory polysaccharide A [PSA], previously shown to be protective in murine models of colitis, were not
detected more often from healthy versus inflamed tissue.
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Introduction
Inflammatory bowel diseases, which include Crohn’s disease
[CD] and ulcerative colitis [UC], are chronic, inflammatory,
disorders of the gastrointestinal tract defined by clinical, patho-
logical, endoscopic, and radiologic features [1]. The precise
etiology of IBD is unknown. The current predominating
hypothesis is that intestinal inflammation in IBD arises from an
exaggerated immune response to the intestinal microbiota in
genetically predisposed individuals. A role for intestinal bacteria in
the pathogenesis of IBD is supported by clinical data. Patients who
undergo surgical diversion of the fecal stream revert to uninflamed
healthy intestines. However, when this previously excluded
intestinal epithelium is re-exposed to the microbial laden fecal
stream, inflammation recurs [2]. In addition, antibiotics that target
anaerobic gut bacteria have shown some efficacy in the treatment
of IBD [3,4].
Multiple studies have shown that the most numerically
dominant bacteria in the human gut belong to two phyla: the
Gram negative Bacteroidetes and the Gram positive Firmicutes
[5]. The human gut Bacteroidetes are largely contained within the
order Bacteroidales, which includes over 20 abundant human gut
species. As fecal/luminal bacterial communities differ from
mucosal communities [6], and the site of inflammation in IBD
occurs at the mucosal surface, several studies have analyzed the
mucosal associated bacterial population in IBD [7,8,9]. No clear
consensus has been reached about total Bacteroidales levels or
Bacteroidales species distribution between IBD subjects and
controls, or between CD and UC [7,9]. However, Bacteroidales
have been consistently shown to predominate at the mucosal
surface where they are more transcriptionally active than
Firmicutes [10].
Because Bacteroidales occupy a vital niche at the intestinal
mucosal surface, they are able to interact with the host and have
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including mucosal barrier fortification [11], intestinal immune
maturation [12], and angiogenesis [13]. Bacteroidales species can
confer either beneficial or detrimental properties to the host
depending upon their genetic content. Bacteroides fragilis type strain
NCTC9343 synthesizes a polysaccharide [PSA] demonstrated to
suppress colitis in an experimental animal model [12,14].
However, only 26% of the B. fragilis strains analyzed were shown
to synthesize the same PSA molecule as the type strain [15] and
therefore, not all B. fragilis strains may have this immunomodu-
latory capability. In addition, some B. fragilis strains produce an
enterotoxin which induces colitis and colon cancer in animal
models and has been associated with colitis flares in human studies
[16]. Due to the extensive genetic and phenotypic variability of
these organisms, geno- and phenotyping of B. fragilis strains from
IBD patients is important to determine if there is a correlation
between the presence B. fragilis strains synthesizing these molecules
at the mucosal surface, and the progression or amelioration of
disease.
Mouse models of IBD have shown that Bacteroidales species
interact differently with the host depending on the immunological
defect and the particular bacterial species used [reviewed [17]].
For example, gnotobiotic -HLA-B27 transgenic rats develop colitis
when monoassociated with B. vulgatus, but not with Escherichia coli
or Enterococcus faecalis [18]. However, gnotobiotic IL-10 KO mice
monoassociated with B. vulgatus develop colitis but not with E. coli
or E. faecalis [19]. Conventionally housed mice, with a double
knock out of the IL-10 receptor 2 and a dominant negative TGF-b
[a combination of pathways often defective in subjects with IBD],
developed intestinal inflammation only in the presence of certain
Bacteroidales species [20]. Furthermore, treatment with antibiotics
targeting Bacteroidales ameliorated disease [20]. This differential
effect of Bacteroides species in IBD mouse models suggests the
importance of characterizing Bacteroidales species distribution at
the gut mucosal surface of IBD patients.
Pediatric IBD is increasing in incidence and in younger patients
[21]. Pediatric patients often have a more aggressive disease and a
more rapid progression. However, only two prior studies have
examined intestinal biopsy tissue from pediatric subjects with IBD
[22] [23]. These studies had fewer patients and biopsies, and did
not speciate or phenotypically characterize the resulting strains.
Our study is the largest study using biopsy tissue from pediatric
and young adult subjects with IBD including both treatment naive
patients and those with pre-existing IBD. In this study, we
performed a comprehensive culture-based analysis of Bacteroi-
dales from mucosal biopsy tissue from pediatric subjects with CD,
UC, and control subjects.
This study addresses several objectives. Using culture based
methods, we quantified total mucosal Bacteroidales from IBD and
control subjects to determine if the levels increased or decreased
with the inflammatory state. We characterized which species of
Bacteroidales are present at inflamed and non-inflamed mucosal
sites in IBD subjects and in healthy control subjects and found
previously unreported differences in Bacteroidales species distri-
bution. We tested Bacteroidales isolates for strain specific features
previously postulated to be protective or pathogenic in IBD. We
assessed pro-inflammatory factors such as toxin production by B.
fragilis, and the ability of Bacteroidales to use mucin as a carbon
source, both features associated with diminishing host immune
defenses [16,24]. We also assessed production of immunomodu-
latory PSA shown to be protective in murine colitis models. This
study is the first to contain phenotypic analyses of the adherent
Bacteroidales population from pediatric IBD subjects.
Materials and Methods
Patients and acquisition of samples
This study was approved by the Institutional Review Board of
Boston Children’s Hospital and informed written consent was
obtained from study subjects and/or their legal guardians.
Subjects with previously diagnosed or suspected IBD undergoing
colonoscopy were recruited as well as control subjects without IBD
or other intestinal inflammatory disease. Subjects were recruited at
Boston Children’s Hospital Gastroenterology endoscopy unit. 39
subjects had CD, 24 subjects had UC, and there were 31 control
subjects (Table 1). Twelve subjects with CD and five subjects with
UC were newly diagnosed. The majority (84%) of our subjects had
three biopsies taken (4 subjects had only 2 biopsies, and the first 6
subjects had six biopsies) with standard forceps from the terminal
ileum, cecum to descending, and recto-sigmoid colon from grossly
inflamed (when present) and non-inflamed sites [Table S1]. The
presence or absence of inflammation was determined by
histopathological review revealing that 79% of subjects with IBD
had any degree of inflammation, and 41% were classified as
moderate to severe inflammation. Control subjects did not have
histologic evidence of intestinal inflammation detected on any of
their biopsies. Inflammation status and sample location are
indicated in Table S1. There were no significant differences in
mean age (P=0.22) or gender (P=0.45) between control, CD, or
UC cohorts. Disease phenotyping followed the Montreal classifi-
cation [25] and disease activity was assessed using the Pediatric
Ulcerative Colitis Activity Index (PUCAI) [26] and Pediatric
Crohn’s Disease Activity Index (PCDAI) [27]. Other documented
clinical parameters included medications, prior surgery, and
disease activity. Control subjects with esophagitis or gastritis had
no detected granulomas. Control subjects were ultimately diag-
nosed with one or more the following: gastroesophageal reflux [9],
functional abdominal pain [6], constipation [4], irritable bowel
syndrome [5], isolated rectal bleeding [2], Helicobacter pylori gastritis
[2], non-specific severe gastritis [1], Meckel’s diverticulum [1], and
infectious diarrhea [1]. Some control subjects had autoimmune
disorders; subject 8 has rheumatoid arthritis, subject 19 has
cutaneous plaque morphia, subject 30 has psoriasis and psoriatic
arthritis, subject 50 has type 1 diabetes, and subject 96 has
multiple sclerosis.
Biopsy Processing and Culture
Each biopsy was placed in sterile 0.9% NaCl [saline] and
transported to the laboratory at room temperature for immediate
processing. Biopsies were washed three times by vigorously
shaking with saline to remove non-adherent bacteria. Biopsies
were then homogenized using a manual pestle in an eppendorf
tube. Samples were diluted in PBS and plated on Brucella laked
blood, kanamycin, vancomycin (LKV) plates (PML Microbiologi-
cals, Durham, NC, USA), which are selective for Bacteroidales. All
species of Bacteroides, Parabacteroides, and Prevotella tested grew on
these plates. Alistipes species were excluded from this study as it was
unclear whether these organisms grow under these culture
conditions. The plates were placed in an anaerobic chamber at
37uC for 4 days. Dilution plates with between 20–200 colonies
were recorded [usually the 10
24,1 0
23 or 10
22 plates] and the
species were identified by a series of multiplex PCR assays
(Table S2). If colonies were only detected on the 10
21 plate, these
numbers were recorded. All colonies on the highest dilution plate
were identified at the species level and several isolates representing
different colony phenotypes (large, small, mucoid, color) on the
second highest dilution plate were identified. The number of
colonies analyzed ranged from 0–73 (mean 34.5614.5 standard
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biopsy (depending on colony phenotypes). One isolate of each
species from an inflamed and non-inflamed site identified at each
time point was frozen at 280uC.
Multiplex PCR assays
The multiplex PCR assays are based on the design of Liu et. al.
[28] and take advantage of the variable region between the 16S
and 23S rRNA genes. All primers used in this study are listed in
Table S2. Taq Mastermix (New England Biolabs Inc. Ipswich,
MA, USA) was used for all PCRs and the conditions were as
follows: multiplex I, 2 minutes 94uC, then 35 cycles of 94uC3 0s ,
59uC3 0s ,6 8 uC 45 s with a final 60 s extension at 68 uC. The
same conditions were used for multiplex II except the annealing
temperature was 52uC. PCR products were resolved on 1.4%
agarose gels. Larger colonies were first screened using multiplex I,
if the species was not identified, multiplex II was performed. Small
colonies were first screened using multiplex II, followed by
multiplex I if they were negative with multiplex II. In total, 1450
isolates were speciated using this multiplex PCR. Additional
primers were used to differentiate species that showed inconclusive
results as previously described [42]. 134 isolates were analyzed to
differentiate B. vulgatus from B. dorei; 61 isolates were screened to
differentiate B. ovatus from B. xylanisolvens and B. acidifaciens; and 34
strains were screened to differentiate B. fragilis from B. finegoldii. All
isolates identified as B. stercoris by multiplex PCR were further
analyzed by sequencing the 286 bp 16S gene region. Isolates
unresolved by multiplex PCR, or the above primer sets, were
speciated by sequencing a 286 bp region of the 16S gene region or
the full 16S gene (Table S2). In total 120 isolates had the 286 bp
region sequenced, and full 16S sequencing was performed for an
additional 26 isolates.
PCR screening of B. fragilis isolates for the enterotoxin
gene [bft]
PCR was performed using previously described primers
(Table S2), which amplify all three isoforms of bft [29] with the
following PCR conditions: 95uC for 2 min and then 32 cycles of
95uC for 30 s, 62uC for 30 s, and 68uC for 60 s. In total, 104 B.
fragilis isolates were screened for the presence of bft.
B. fragilis polysaccharide A [PSA] dot blot
Three mlo fB. fragilis grown to stationary phase were dotted on
nitrocellulose membranes. The primary antibody was monoclonal
antibody CE3 to the PSA of type strain B. fragilis NCTC 9343
[15]. The secondary antibody was an alkaline phosphatase-
conjugated goat-anti-mouse IgG (Sigma-Aldrich, St. Louis, MO,
USA). Blots were developed with phosphatase substrate (KPL,
Gaithersburg, MD, USA). Any isolate that produced an ambig-
uous result was retested by Western immunoblot with the same
primary and secondary antibodies. In total, all 113 isolates of B.
fragilis that were retained as frozen stocks were analyzed.
Growth of strains on defined mucin agarose plates
Defined medium agarose plates [30] lacking glucose and
containing 0.3% porcine gastric mucin (Sigma-Aldrich, St. Louis,
MO, USA) as the sole utilizable carbon source were inoculated
with strains and incubated anaerobically for 96 hours, at which
time growth was monitored. Fourteen Bacteroidales species were
tested on these defined agarose plates [30] lacking mucin and none
grew.
Statistical Analysis
Study data were collected and managed using REDCap
electronic data capture tools hosted at Boston Children’s Hospital
[31]. REDCap (Research Electronic Data Capture) is a secure,
web-based application designed to support data capture for
research studies, providing [1] an intuitive interface for validated
data entry [2] audit trails for tracking data manipulation and
export procedures [3] automated export procedures for seamless
data downloads to common statistical packages, and [4] proce-
dures for importing data from external sources. Statistical analysis
was conducted in SAS version 9.2 (SAS Institute, Cary, NC) and
Table 1. Study population demographics and disease phenotype.
Control (n=31)
Crohn Disease
(n=39)
Ulcerative Colitis
(n=24)
Age (years) Mean 6 SD (P=0.22) 14.663.8 15.364.6 16.664.5
Range 7.1–22.9 5.1–23.4 3.7–23.6
Female (P=0.45) 19 18 13
Immunosuppressed 12 1 8
Montreal criteria Ileal disease (L1) 10
Colonic disease (L2) 3
Ileocolonic disease (L3) 26
Isolated upper tract disease 0
Non-Stricturing/Penetrating (B1) 29
Stricturing/Penetrating (B2/B3) 9
Perianal Disease (P) 16
Ulcerative colitis type Pancolitis (E1) 11
Left sided colitis (E2) 11
Proctitis ,15cm (E3) 2
1. n=subject.
2. Immunosuppressed is defined as any patients taking immunomodulators and/or biologics.
doi:10.1371/journal.pone.0063686.t001
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Redmond, Washington: Microsoft, 2003, Computer Software).
Categorical data were summarized as N (%) and comparisons
across groups made by the Pearson Chi-Square statistic, or
Fisher’s exact test when the expected cell count was ,5 in one or
more cross-tabulation table cells. Continuous variables were
summarized according to their distribution: mean 6 SD if
normally distributed; median (inter-quartile range) if skewed right
or left. The method for group comparisons for continuous
variables was likewise chosen to suit the distribution of outcome.
Student’s t-test was used to compare normally distributed variables
between two independent groups, and analysis of variance in the
case of three or more independent groups. Non-parametric
equivalents (Wilcoxon rank-sum test; Kruskal-Wallis test) were
used otherwise. Generalized estimating equations [GEE] were
used to compare means across groups, controlling for within-
subject correlation. All tests of significance are 2-sided with
P,0.05 indicating statistical significance. The correlation of total
Bacteroidales per biopsy with number of species identified per
biopsy was examined using Spearman rank correlation.
Results
Total Bacteroidales per biopsy by cohort and degree of
inflammation
Because some studies have shown that Bacteroidales differ in
quantity at inflamed sites, we analyzed IBD cohorts by degree of
inflammation combining moderate to severely inflamed biopsies,
and biopsies with no or mild inflammation. Total adherent
Bacteroidales ranged from zero to 4 log colony forming units (cfu)
per biopsy. Total Bacteroidales per biopsy did not differ
significantly based on biopsy location from terminal ileum to
rectum (data not shown). Control biopsies had a mean 6 SD of
3.060.9 cfu/biopsy which was not statistically different than the
combined IBD cohort mean 6 SD of 2.961.0 cfu/biopsy P=0.74
(Table 2). When examining the entire IBD cohort, total Bacteroi-
dales among inflamed biopsies were similar mean 6 SD 2.861.1
to uninflamed IBD biopsies 3.061.0 P=0.28.(Figure 1A, Table 2).
When examined by severity of inflammation or comparing UC
and CD, no significant differences in total Bacteroidales per biopsy
were detected. Analysis of treatment naive subjects showed no
significant differences in total Bacteroidales per biopsy by cohort
or by degree of inflammation (Figure 1B, Table S3).
All but two control subjects (4, 50) had at least 10 cfu/biopsy,
and usually more, whereas five UC subjects (9, 18, 55, 90, and 99)
and six CD subjects (17, 27, 54, 65, 70, and 76) had no
Bacteroidales detected on one or more of their biopsies. Of these
five UC subjects, one (99) had no Bacteroidales detected on any
biopsies and one (18) had Bacteroidales only detected on one
biopsy at a low level (10 cfu/biopsy). Of the six with CD, one
subject (76) had no Bacteroidales detected on any biopsies, and
five subjects (17, 27, 54, 65, and 70) had none detected on just one
biopsy. When subtracting the two newly diagnosed subjects with
CD from the group, seven of eight had one characteristic in
common, they were on a 5-aminosalicylic acid medication (5-ASA)
alone or in combination with other anti-inflammatory medica-
tions.
Species Identification and Diversity
In total, from all subjects and sites, 18 different Bacteroidales
species were identified: 14 Bacteroides species, two Parabacteroides
species, a Dysgonomonas gadei and Odoribacter splanchnicus [Porphyr-
omonadaceae family] and a Prevotella bivia [Prevotellaceae family].
Infrequently, non-Bacteroidales species that had acquired antibi-
otic resistance allowing them to grow on these selective plates were
detected. These species were Clostridium innocuum, Pediococcus
acidilactici, E. coli, Staphylococcus epidermidis, Propionibacterium acnes,
Proteus sp., and Staphylococcus sp. There was a positive correlation of
0.47 (P,0.0001) between total Bacteroidales concentration per
biopsy with the number of species identified per biopsy, by
Spearman rank correlation.
In total, we identified between 0–9 different Bacteroidales
species per biopsy (controls: 0–9, CD 0–7, UC 0–9) (Figure 2).
Species diversity did not differ significantly in biopsies from IBD
subjects compared to controls, nor did it differ significantly
between IBD subtypes CD and UC (Table 2). Similarly, there
were no significant differences in species diversity in biopsies from
newly diagnosed subjects (Table S3). However, fewer unique
Bacteroidales species were detected on moderate and severely
inflamed IBD biopsies (median (IQR) =2 (1, 3) compared to
mildly inflamed or uninflamed IBD tissue (median (IQR) =3 (2,
4); P=0.03) (Figure 3, Table 2).
Distribution of Bacteroidales species between IBD
cohorts and between IBD and control biopsies
Species analyses yielded several statistically significant differ-
ences between CD, UC, and control groups. P. distasonis was
present on (38%) of control biopsy samples compared to (14%) of
CD biopsies (P=0.003). B. cellulosilyticus was also present more
Figure 1. Total Bacteroidales (cfu/biopsy) by cohort and degree
of inflammation. Biopsies were grouped by cohort: CD (Crohn
Disease), UC (ulcerative colitis) and Control and degree of inflammation:
no and mild inflammation (no/mild) or moderate to severe inflamma-
tion (mod/svr). N is equivalent to the number of biopsies in each group.
Column level represents mean Bacteroidales log cfu/biopsy. Error bars
represent inter-quartile ranges A. Entire cohort. There were no
significant differences detected between cohorts. B Includes only
biopsies from newly diagnosed subjects.
doi:10.1371/journal.pone.0063686.g001
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(P=0.04). B. vulgatus was present on significantly fewer biopsy
samples from UC subjects (25%) compared to subjects with CD
(53%, P=0.03) and control subjects (51%, P=0.05, Table 3).
Distribution of Bacteroidales species in newly diagnosed
subjects compared to those with longstanding disease
Separate analyses of newly diagnosed IBD subjects were
performed to avoid the potential effects that non-antibiotic
medications may have on species distribution (Table S4). The
distribution of P. distasonis had a similar trend to that of the entire
cohort. P. distasonis remained significantly higher in controls
compared to newly diagnosed patients with CD or UC in
comparison to control subjects (P=0.04 CD and P=0.03 UC,
Table S4). B. finegoldii was detected less often on control biopsies
compared to UC biopsies (P=0.01). However, in the cohort of
new diagnoses, unique statistically significant differences emerged
in the distribution of B. thetaiotaomicron and B. caccae that were not
seen in the all inclusive cohort. B. thetaiotaomicron was more
commonly present in UC compared to controls (P=0.02) and
compared to CD (P=0.02). B. caccae was detected more often in
newly diagnosed CD (45%) versus controls (15% P=0.02) and UC
versus control (P=0.05) (Table S4, Figure 2). Some differences in
species distribution between the newly diagnosed cohort were
detected (Table 3, Table S4) suggesting duration of disease and/or
that anti-inflammatory medications may modulate species distri-
bution on the intestinal surface.
Bacteroidales species from inflamed and uninflamed
biopsies
In general, species detected on multiple biopsies within an
individual showed a similar species distribution (Figure 2, Table 3
and S4). There were typically fewer species detected at inflamed
areas compared to uninflamed areas within an individual (Figures 2
and 3). However, when comparing particular species distribution
by degree of inflammation within our IBD cohorts, a few
significant differences were observed. P. distasonis was detected
on none of the moderate and severely inflamed biopsies from CD
subjects and on 17% of biopsies with no or mild inflammation
(P=0.04). In newly diagnosed subjects, no statistical differences
were found in species distribution between moderate and severely
inflamed biopsies compared to mildly inflamed and uninflamed
biopsies (data not shown). This was likely due to lower number of
samples in each group providing inadequate power. We compared
CD and UC biopsies with moderate and severe inflammation to
those from control subjects in order to assess the effect of
inflammation on species distribution. We detected decreased B.
vulgatus in UC compared to control biopsies (P=0.02, Table S5).
Medication Effects
5-aminosalicylic acid, (5-ASA) Medications: 5-ASA has been
proposed to affect bacterial growth and the amount of mucosal-
associated bacteria. 12/39 of the CD subjects, 17/24 of the UC
subjects, and 1/31 control subjects were treated with a 5-ASA
medication at the time of sample collection. There was no
statistically significant difference in total Bacteroidales concentra-
tion on biopsies from subjects receiving 5-ASAs. However, there
was a significant decrease in Bacteroidales diversity (number of
detected species) at inflamed sites in patients treated with 5-ASA,
mean 6 SD 2.161.9, compared to 4.262.6 in patients not on 5-
ASA (P=0.03). The only significant species difference associated
with 5-ASA treatment was a decrease in B. vulgatus at moderate to
severely inflamed sites (P=0.01).
Species diversity and total Bacteroidales per biopsy
comparing medications other than 5-ASA
Previous groups have shown that anti-inflammatory medica-
tions used alone or in combination to treat IBD may have effects
on the microbiota [32]. We compared species diversity (number of
different Bacteroidales species detected by subject), and total
Bacteroidales (cfu/biopsy) in IBD subjects compared to six control
subjects who were not receiving medications. We compared
medications alone and in combination (data not shown). There
were no significant differences detected for either of these analyses,
possibly due to the small number of subjects in each group.
Bacteroidales growth on mucin
The Bacteroidales species detected in this study were predom-
inant species adherent to the mucosal surface. The presence of
Bacteroidales embedded in the mucosal surface is potentially
associated with the ability of these bacteria to utilize mucin as a
source of nutrients. We tested 373 of our isolates for their ability to
grow on defined mucin plates where mucin is supplied as the only
utilizable carbon source. Every strain tested grew on minimal
Figure 2. Heatmaps of Bacteroidales species distribution and concentration by cohort. A. Control cohort. B. UC cohort. C. CD cohort.
Bacteroidales species are labeled at the top of the figure. Subject numbers are listed on the left. Each row represents the species detected on that
subject’s biopsy (In cases where more than one biopsy of the same degree of inflammation was present, the detected species levels (cfu/biopsy) from
each biopsy was averaged and all detected species from both biopsies were included). The degree of inflammation of the biopsy is indicated to the
right of the biopsy (N: Non-inflamed, Mild, Mod: Moderate, or Svr: Severe). White lines demarcate biopsies from one subject.
doi:10.1371/journal.pone.0063686.g002
Figure 3. Bacteroidales species diversity by degree of inflam-
mation. The median number of species per IBD biopsy detected from
biopsies with no or mild inflammation (No/Mild) compared to IBD
biopsies with moderate to severe inflammation (Mod/Svr). Error bars
represent inter-quartile ranges. N equals the number of biopsies in each
group. *P=0.02.
doi:10.1371/journal.pone.0063686.g003
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dorei, 27; B. eggerthii,7 ;B. finegoldii,13; B. fragilis, 50; B. intestinalis,3 ;
B. ovatus, 38; B. stercoris, 13; B. thetaiotaomicron, 35; B. uniformis, 32; B.
vulgatus, 46; B. xylanisolvens, 18; P. distasonis, 36; P. merdae, 24; and
Dysgonomonas gadeii 1.
Detection of bft [B. fragilis toxin gene]
bft encodes for an enterotoxin that has been associated with
colitis flares, colon cancer and diarrhea [33]. B. fragilis isolates
cultured from biopsy tissue were screened by PCR for the presence
of the bft gene. In total, 104 B. fragilis isolates were screened; 40
from control tissue, 21 from non-inflamed CD biopsies, and 20
from inflamed CD biopsies, 10 from non-inflamed UC biopsies,
and 13 from inflamed UC biopsies. Of these 104 B. fragilis isolates,
only six were bft positive (Figure 4, Table 4). Of these six bft
positive isolates, three isolates were from biopsy tissue from control
subjects (two biopsies were from the same control subject), one was
from an uninflamed CD biopsy, and the remaining two were from
uninflamed and inflamed biopsies from the same subject with UC.
There were no statistically significant differences detected between
UC and CD, between IBD and controls, or between strains from
inflamed and uninflamed sites.
Analysis of PSA1 producing B. fragilis isolates
Each strain of B. fragilis synthesizes eight distinct capsular
polysaccharides termed PSA-PSH [34]. For type strain NCTC
9343, the PSA polysaccharide [PSA1] is a zwitterionic molecule
with immunomodulatory properties implicated in the amelioration
of colitis [14]. As different strains of B. fragilis produce different
Table 3. Comparison of Bacteroidales species, by disease status (IBD vs. controls) and study group (CD, UC, and controls).
IBD vs Controls Type of IBD
Secondary
Hypothesis Tests
Bacteroidales species
1
IBD
(n=192)
2
Control
(n=97)
2 P
CD
(n=121)
2
UC
(n=71)
2
Control
(n=97)
2
PCD vs
UC
PCD vs
Ctrl
PUC vs
Ctrl
P. distasonis 32 (17%) 37 (38%) 0.004 17 (14%) 15 (21%) 37 (38%) 0.37 0.003 0.10
B. fragilis 84 (44%) 49 (51%) 0.47 54 (45%) 30 (42%) 49 (51%) 0.85 0.57 0.49
B. thetaiotaomicron 40 (21%) 29 (30%) 0.23 24 (20%) 16 (23%) 29 (30%) 0.76 0.24 0.45
B. uniformis 35 (18%) 31 (32%) 0.07 23 (19%) 12 (17%) 31 (32%) 0.80 0.14 0.10
B. vulgatus 82 (43%) 49 (51%) 0.43 64 (53%) 18 (25%) 49 (51%) 0.03 0.82 0.05
B. ovatus 51 (27%) 26 (27%) 0.97 33 (27%) 18 (25%) 26 (27%) 0.84 0.96 0.88
B. caccae 45 (23%) 15 (15%) 0.32 29 (24%) 16 (23%) 15 (15%) 0.88 0.32 0.46
P. merdae 26 (14%) 23 (24%) 0.15 15 (12%) 11 (15%) 23 (24%) 0.68 0.14 0.38
B. cellulosilyticus 4 (2%) 8 (8%) 0.08 1 (1%) 3 (4%) 8 (8%) 0.18 0.04 0.44
B. dorei 44 (23%) 16 (16%) 0.40 22 (18%) 22 (31%) 16 (16%) 0.22 0.83 0.16
B. intestinalis 2 (1%) 0 (0%) -- 1 (1%) 1 (1%) 0 (0%) -- -- --
B. stercoris 18 (9%) 10 (10%) 0.85 11 (9%) 7 (10%) 10 (10%) 0.90 0.83 0.94
B. eggerthii 7 (4%) 4 (4%) 0.87 5 (4%) 2 (3%) 4 (4%) 0.67 1.00 0.67
Dysgonomonas gadei 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) 0 (0%) -- -- --
B. xylanisolvens 19 (10%) 5 (5%) 0.41 7 (6%) 12 (17%) 5 (5%) 0.19 0.10 0.15
B. finegoldii 24 (13%) 2 (2%) 0.08 15 (12%) 9 (13%) 2 (2%) 0.97 0.09 0.10
Prevotella bivia 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) 0 (0%) -- -- --
B. acidifaciens 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) 0 (0%) -- -- --
P-value from generalized estimating equation, controlling for within-subject correlation.
1. B= Bacteroides, P= Parabacteroides.
2. n is equivalent to the number of biopsies per cohort.
--: Prevalence too small for valid test of significance by GEE.
doi:10.1371/journal.pone.0063686.t003
Figure 4. PCR analysis of bft from B. fragilis isolates. Lane one
contains a bft containing strain (086 care of C. Sears, MD). Lane two
contains a B. fragilis strain without bft (9343). Lane three contains an
isolate from the terminal ileum (TI) of subject 34. Lanes four and five
contain isolates from TI and ascending colon biopsies from control
subject 43. Lane 6 contains an isolate from the non-inflamed terminal
ileum of a subject 71 with CD. Lane 7 contains an isolate from an
inflamed TI biopsy of subject 64 with CD. Lanes 8 and 9 contains
isolates from non-inflamed rectal and inflamed ascending colon
biopsies of a subject 74 with CD. Lanes 10 and 11 are isolates from
non-inflamed TI and inflamed descending colon biopsies of a subject 39
with UC. Lanes 12 and 13 are isolates from an non-inflamed cecal
biopsy and inflamed rectal biopsy from subject 62 with UC.
doi:10.1371/journal.pone.0063686.g004
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samples to determine if the presence of strains producing this
molecule were present more frequently from healthy mucosal
tissue. A monoclonal antibody specific to the NCTC 9343
immunomodulatory PSA type [PSA1] was used [15,35,36]. In
total, 59 B. fragilis isolates were screened of which, 20 (34%)
reacted with the monoclonal antibody to the PSA of the type
strain. Despite the anti-inflammatory properties described for this
molecule, PSA1-producing B. fragilis were not found more
frequently at non-inflamed sites in subjects with IBD compared
to uninflamed sites. PSA1 producing B. fragilis were present on
seven of 14 inflamed biopsies from CD subjects and two of seven
inflamed biopsies from UC subjects. In addition, there was not a
statistically significant difference between the presence of muco-
sally adherent PSA1-producing B. fragilis from controls versus IBD
samples (P=0.73). There were also no statistically significant
differences in PSA1 producing B. fragilis adherent to the mucosa at
inflamed and uninflamed sites in CD (P=0.68) or UC (P=1.0). (P
values were determined using a Fishers exact test to compare each
group). A newly diagnosed subject with CD had a PSA1 positive B.
fragilis isolate at both an inflamed and non-inflamed site. The B.
fragilis strains from the same individual tended to all synthesize the
immunomodulatory PSA or were all negative for this molecule
regardless of inflamed or non-inflamed site (Table 4, Figure 5).
However in one CD subject (56), two different B. fragilis strains
were detected on the same inflamed sample, one producing the
immunomodulatory PSA1 molecule, and one producing a
different PSA type.
Discussion
In this study, we quantified and identified to the species level
mucosally adherent Bacteroidales species from the intestine of
pediatric and young adult patients with IBD and controls. We
focused on the Bacteroidales for several reasons. Bacteroidales
occupy a vital niche at the intestinal mucosal surface where they
have the potential to influence the host. Numerous studies have
implicated Bacteroidales species in IBD [20,37,38]. In addition,
Bacteroidales have been shown to modulate host immune and
intestinal functions [12,39]. No other study has classified Bacteroi-
dales to the species level as comprehensively as this study and no
other study used a culture based approach, which is the most
accurate quantitative method. Within our cohort, we obtained
biopsies from newly diagnosed IBD subjects, as well as subjects
with longstanding disease. We collected detailed phenotypic
information about our subjects, which allowed us to make
observations regarding variables such as the severity of inflamma-
tion and potential medication effects. In addition, we created a
valuable strain bank from which we could perform further
phenotypic analyses of the isolated strains.
Several studies have reported increases or decreases in Bacteroi-
dales in mucosal samples of IBD subjects compared to controls
[8,37,40,41], some also compare inflamed and non-inflamed sites
[42]. No clear trend has emerged regarding total Bacteroidales in
IBD. Unlike DNA-based approaches, our culture-based method
guarantees precise measurements of live bacteria. We found no
significant differences in total number of adherent Bacteroidales in
IBD versus control or between CD and UC. There was large inter-
individual variation in total Bacteroidales detected across our
cohort- from a few subjects with no detected Bacteroidales to those
with log 4 cfu/biopsy. The log scale variability in total Bacteroi-
dales by IBD cohorts and between individuals is consistent with
other studies which performed anaerobic culture of biopsies [43]
[44]. This suggests there is not a ‘‘normal’’ amount of Bacteroi-
dales present on all mucosal surfaces across subjects and may
explain the varied conclusions of prior studies. There is a
molecular basis for why the Bacteroidales are able to survive at
inflamed sites. B. thetaiotaomicron has been shown to adapt to
inflammation by turning on genes that metabolize host oxidative
products [45] suggesting that at least some Bacteroides species may
be better suited to survive in inflamed regions. As our study
demonstrated numerous Bacteroidales species can survive at
inflamed sites, this may be a shared feature of intestinal
Bacteroidales species.
One of our significant findings was a decrease in Bacteroidales
diversity, [number of different Bacteroides species per biopsy] at
sites with increased inflammation in IBD subjects. Previous reports
detected decreased bacterial diversity in IBD subjects compared to
Table 4. Number of biopsies with B. fragilis where bft or PSA
was present.
Control CD NI CD I UC NI UC I
bft positive B. fragilis
1 2/40 1/21 0/20 1/10 1/13
PSA1 positive B. fragilis
2 9/20 5/12 4/14 1/6 2/7
Abbreviations: CD= Crohn Disease, UC= Ulcerative Colitis, I= Inflamed biopsy
tissue, NI= Non-Inflamed biopsy tissue where isolate originated.
Denominator represents all biopsies in a cohort where B. fragilis was detected
and numerators indicate:
1. bft detected by PCR. (No statistically significant differences were detected
between groups).
2. PSA1 detected by immunoblot. (No statistically significant differences were
detected between groups).
doi:10.1371/journal.pone.0063686.t004
Figure 5. PSA analysis of B. fragilis isolates. A Western blot of PSA
from B. fragilis isolates grown in vitro after isolation from control, CD
and UC (inflamed (I) a non-inflamed (NI) biopsies. Panel A: Lanes 1–6
contain B. fragilis isolates from the biopsies control subjects (4, 6, 13, 34,
68, and 1). Lanes 7–8 contain isolates from non-inflamed and inflamed
biopsies from subject 23 with UC. Lanes 9–11 contain isolates from
inflamed and uninflamed biopsies from subjects with UC: 32, 29 and 77.
Panel B: Lane 1 contains B. fragilis type strain 9343 as a positive control.
Lanes 2 and 3 contain isolates from a non-inflamed and then an
inflamed biopsy from subject 47 with CD. Lanes 4–8 contain B. fragilis
isolates from inflamed biopsies of subjects 26, 56, 64, 14, and 85 with
CD.
doi:10.1371/journal.pone.0063686.g005
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increased inflammation. In general, we noted larger inter-
individual variation and less intra-subject variation at the species
level, similar to what other studies have shown with multiple
colonic biopsies from one individual [46] [9] [6] and in multiple
stool samples from the same individual [47].
There were no Bacteroidales species signatures for CD, UC or
control biopsies. However, there were statistically significant
differences in certain species between cohorts. P. distasonis was
found more often in control subjects compared to CD subjects in
both newly diagnosed subjects and those with longstanding
disease. Its predominance at healthy and uninflamed sites suggests
a preference for adherence to ligands at uninflamed host sites, or
greater susceptibility to host inflammatory products. A recent
study reported a decrease of all Parabacteroides spp. at inflamed
compared to uninflamed sites [9], similar to our findings. Fecal
samples from pediatric subjects with IBD noted a similar decreases
in Parabacteroides in IBD subjects versus controls [48]. The only
other two pediatric studies which examined the microbiota of
intestinal biopsies found no difference in P. distasonis between IBD
subjects and controls [22] [23]. Interestingly, a recent study
demonstrated that oral administration of the membranous fraction
of P. distasonis significantly reduced the severity of intestinal
inflammation in murine models of colitis induced by dextran
sulphate sodium (DSS) [49].
B. thetaiotaomicron and B. fragilis contain enzymes that will
partially desulphate mucins [50] which may be a feature shared
among all Bacteroidales. The ability to degrade mucin has been
suggested as a way that members of the intestinal microbiota may
contribute to chronic inflammation, by compromising the
protection mucin provides the host epithelium [24,51]. We
examined the ability of the strains from this study to utilize mucin
as a carbon source for growth. All 373 of the strains we examined,
comprising 16 different Bacteroidales species, were able to grow
on plates with mucin as the sole utilizable carbon source. Since this
is a feature of all isolated Bacteroidales from both inflamed and
uninflamed sites, it is likely that this common feature has a primary
role in nutrient acquisition.
Some strains of B. fragilis produce an enterotoxin [Bacteroides
fragilis toxin, bft], which is correlated with pediatric diarrheal
disease, colitis flares, colon cancer, and exacerbation of colitis in
mouse models [reviewed [33]]. There were no differences in
presence of bft positive B. fragilis isolates between IBD subjects and
controls or between inflamed an uninflamed tissue, although very
few bft
+ B. fragilis isolates were identified in total. One prior study
of an older cohort (mean age 45) detected bft
+ B. fragilis isolates
more frequently from colonoscopic washings of active IBD
patients than stool from control subjects [38]. Another study,
found no significant differences in bft
+ and negative strains
between active and inactive inflammation or between IBD
subtypes similar to our findings [52]. We have previously reported
bft carriage in fecal samples from adults as high as 57% of B. fragilis
isolates [47], therefore, it is possible that adults harbor more bft
+ B.
fragilis strains than children.
We investigated an additional strain specific feature of B. fragilis,
the synthesis of an extensively studied immunomodulatory
capsular polysaccharide, PSA. Previous work has shown that B.
fragilis strain NCTC 9343 synthesizing the immunomodulatory
PSA is able to protect mice from Helicobacter hepaticus inflammation
[14]. Only 25% of B. fragilis strains previously analyzed were found
to synthesize the PSA1 molecule [15]. Based on the anti-
inflammatory activity of PSA1, it is possible that PSA1 producing
B. fragilis are present more frequently at uninflamed sites or in
biopsies from control sites versus inflamed sites of IBD patients.
However, we found no significant differences between these
cohorts. As the synthesis of PSA is under complex regulation [34]
[53], it is possible that only a small population of B. fragilis with the
ability to synthesize PSA1 were actually doing so.
5-aminoslicylic acid, 5-ASA has been used for decades to treat
IBD. 5-ASAs affect the host mucosal immune response but also
have been shown to affect distribution, growth, and transcriptional
responses of gut bacteria [54]. Additionally, 5-ASAs have been
shown to decrease total concentrations of mucosal associated
bacteria on human colonic biopsies when compared to control
biopsies or biopsies from subjects treated with azathioprine [32].
Our study showed 5-ASAs decreased mucosally adherent Bacter-
oidales diversity at sites of increased inflammation. As Bacteroi-
dales and Firmicutes are the predominant bacterial phyla at the
colonic mucosal surface, some of the therapeutic effect of 5-ASAs
may be by decreasing the host’s bacterial burden at mucosal sites.
Further studies are need to investigate if Bacteroidales growth is
affected by the presence of 5-ASA, if any species specific factors
can explain the relative decrease in certain species at inflamed
sites, and if the drug also reduces the mucosal burden of
predominant Gram positive commensal species.
Further study of the mechanisms in which these dominant
commensals interact with the inflamed and healthy host intestinal
epithelium is warranted. Our valuable collection of strains from
inflamed and healthy subjects will provide a resource for further
study.
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